- Home
- EWTX vs CRMD Comparison
EWTX vs CRMD Comparison
Compare EWTX & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- CRMD
- Stock Information
- Founded
- EWTX 2017
- CRMD 2006
- Country
- EWTX United States
- CRMD United States
- Employees
- EWTX N/A
- CRMD N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- EWTX Health Care
- CRMD Health Care
- Exchange
- EWTX Nasdaq
- CRMD Nasdaq
- Market Cap
- EWTX 1.5B
- CRMD 973.3M
- IPO Year
- EWTX 2021
- CRMD 2010
- Fundamental
- Price
- EWTX $13.03
- CRMD $11.62
- Analyst Decision
- EWTX Buy
- CRMD Strong Buy
- Analyst Count
- EWTX 9
- CRMD 7
- Target Price
- EWTX $39.89
- CRMD $17.33
- AVG Volume (30 Days)
- EWTX 892.5K
- CRMD 2.5M
- Earning Date
- EWTX 08-07-2025
- CRMD 08-13-2025
- Dividend Yield
- EWTX N/A
- CRMD N/A
- EPS Growth
- EWTX N/A
- CRMD N/A
- EPS
- EWTX N/A
- CRMD 0.28
- Revenue
- EWTX N/A
- CRMD $82,553,827.00
- Revenue This Year
- EWTX N/A
- CRMD $238.38
- Revenue Next Year
- EWTX N/A
- CRMD $53.52
- P/E Ratio
- EWTX N/A
- CRMD $41.86
- Revenue Growth
- EWTX N/A
- CRMD N/A
- 52 Week Low
- EWTX $10.60
- CRMD $3.61
- 52 Week High
- EWTX $38.12
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- EWTX 35.20
- CRMD 39.52
- Support Level
- EWTX $12.72
- CRMD $12.14
- Resistance Level
- EWTX $13.37
- CRMD $17.43
- Average True Range (ATR)
- EWTX 0.65
- CRMD 0.69
- MACD
- EWTX -0.16
- CRMD -0.51
- Stochastic Oscillator
- EWTX 24.22
- CRMD 4.60
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.